Cingulate Inc.: insider trades · United States · SEC (Form 4)

About Cingulate Inc.

Cingulate Inc. is a clinical-stage biopharmaceutical company listed on the U.S. NASDAQ market in the United States. For French-speaking investors, it is best understood as a focused CNS-oriented small-cap biotech rather than a diversified pharma platform. The company is centered on attention-deficit/hyperactivity disorder (ADHD) and anxiety-related disorders, using its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop branded next-generation pharmaceutical products designed to provide more consistent coverage over the course of the day and reduce the drawbacks associated with multiple-dose regimens. ([cingulate.com](https://www.cingulate.com/investors?utm_source=openai)) Cingulate’s roots are in Cingulate Therapeutics, and its operational base is in Kansas City, in the United States. That geography matters: the company is built around a Midwestern biotech footprint rather than a large coastal pharmaceutical hub. Its strategy has been to build a small number of differentiated assets around PTR™, with the commercial thesis resting on improved dosing convenience, better duration of action, and stronger intellectual property protection than a simple reformulation story. The company describes itself as a Phase 3 clinical-stage biopharmaceutical company focused on innovative product candidates for ADHD and anxiety-associated disorders. ([cingulate.com](https://www.cingulate.com/news-releases/news-release-details/cingulate-therapeutics-announces-expansion-accommodate-growth?utm_source=openai)) The lead program is CTx-1301 (dexmethylphenidate HCl), Cingulate’s flagship ADHD candidate. In October 2025, the U.S. FDA accepted the company’s New Drug Application and assigned a PDUFA target action date of May 31, 2026, making regulatory review the central near-term catalyst. In March 2026, the company said it had received a U.S. patent notice of allowance for CTx-1301 and also secured additional European patent grants, which strengthens the IP narrative around the lead asset. Cingulate also appointed Bryan Downey as Chief Commercial Officer in 2025 to prepare for a potential launch, indicating that management is actively building commercial readiness ahead of a possible approval decision. ([cingulate.com](https://www.cingulate.com/news-releases/news-release-details/cingulate-names-industry-veteran-bryan-downey-chief-commercial/?utm_source=openai)) From a competitive standpoint, Cingulate remains a niche player in a market dominated by much larger ADHD franchises. Its opportunity is tied to whether PTR™ can translate into meaningful clinical and commercial differentiation, particularly for patients and prescribers seeking all-day symptom coverage with fewer dosing issues. At the same time, the investment case remains binary and execution-sensitive because the company is still pre-commercial and dependent on regulatory outcomes, supply-chain preparation, and capital access. Recent corporate updates in 2026 show that Cingulate raised $12 million in a private placement and ended the first quarter of 2026 with a stronger cash position, helping fund operations into the next major milestone. For investors, the story is therefore one of high regulatory leverage, IP-driven differentiation, and concentrated product risk on the NASDAQ in the United States. ([nasdaq.com](https://www.nasdaq.com/press-release/cingulate-announces-closing-12-million-private-placement-priced-market-under-nasdaq?utm_source=openai))